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Abstract
Several recent publications have established a strong
association between anti-cyclic citrullinated peptide antibody
(anti-CCP)-positive rheumatoid arthritis (RA) and carriage of
shared epitope (SE) alleles. Although anti-CCP have also been
associated with more severe RA, the issue of whether this is
independent of rheumatoid factor (RF) has not been addressed.
To identify associations between RF, anti-CCP, SE status and
radiological damage, we studied a large cross-sectional cohort
with longstanding RA. Individuals (n = 872) enrolled in the study
all fulfilled the American College of Rheumatology criteria for
RA, had a minimum disease duration of 3 years, and at least one
definite radiographic erosion was present in hands or feet.
Radiographs were scored blind at study entry by a single
musculoskeletal radiologist using a modified Larsen's score.
Anti-CCP and RF levels were determined using enzyme-linked
immunosorbent assay, and DRB1 typing was performed using
polymerase chain reaction based methodology. Both anti-CCP
and RF levels were strongly associated with radiographic
severity (P < 0.0001). In subgroups stratified for both anti-CCP
and RF status, evidence of independent associations of both
antibodies with radiographic outcome was found (P < 0.0001).
An association of SE alleles with radiographic severity was
present only in RF-negative individuals. Anti-CCP positivity was
associated with SE status with evidence of a gene-dose effect,
most markedly in RF-negative individuals (P < 0.01). Anti-CCP
and RF status are independent severity factors for RA, with SE
alleles playing at most a secondary role. Our data support the
view that previously described associations between SE and
radiological severity, especially in RF-negative patients, may be
indirect and due to an association with anti-CCP.
Introduction
Antibodies to cyclic citrullinated peptides (anti-CCP) exhibit
high specificity for rheumatoid arthritis (RA) [1]. Recent stud-
ies demonstrated that shared epitope (SE) alleles are strongly
associated with anti-CCP-positive but not anti-CCP-negative
RA [2], and indeed are more strongly associated with anti-
CCP than with RA itself [3,4]. These findings lend strong sup-
port to the concept of anti-CCP-positive RA as a distinct entity
[2]. Furthermore, anti-CCP has been shown to influence radi-
ographic progression in prospective studies, with some evi-
dence of an interaction with SE alleles [2,5]. However, the
presence of anti-CCP is associated with the presence of rheu-
matoid factor (RF) [3], which also is an established severity
factor in RA in prospective studies of progression [6] as well
as longstanding disease [7].
Whether associations of anti-CCP with disease severity are
independent of RF remains unclear. The influence of SE alleles
on disease severity appears to vary among populations, with
most studies suggesting an association with erosivity [8]. Sev-
eral studies have suggested that the association of SE alleles
with radiographic outcome is relevant only in RF-negative indi-
viduals [8-10]. Because carriage of SE alleles is associated
with anti-CCP but not RF, it was recently suggested [3] that
effects of SE alleles on disease severity may be indirect and
secondary to an association with anti-CCP. In the present
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study we determined associations between radiographic out-
come in longstanding disease (as assessed by modified
Larsen's score) and RF, anti-CCP and SE alleles. We report
independent associations of RF and anti-CCP with radio-
graphic severity of disease, suggesting that both of these fac-
tors may have important influence on pathways that lead to
joint damage. We concur with previous studies suggesting
that SE alleles are associated with radiographic outcome only
in RF-negative individuals, and confirm a strong association
between anti-CCP status and SE alleles, with evidence of a
gene-dose effect. This association is most striking in RF-neg-
ative individuals, supporting the hypothesis that the associa-
tion of SE alleles with disease severity in RA may act via anti-
CCP.
Materials and methods
Participants
Patients with established RA attending outpatient clinics at the
Royal Hallamshire Hospital, Sheffield, UK were enrolled in the
study between 1999 and 2006. Research ethics committee
approval was obtained for the study (SSREC protocol number
02/186) and all participants gave informed consent. All sub-
jects were white Caucasian, fulfilled the American College of
Rheumatology criteria for RA [11], had a minimum disease
duration of 3 years, and had at least one definite radiographic
erosion in hands or feet. Radiographs of hands and feet were
scored blind at study entry by a single musculoskeletal radiol-
ogist (DJM) using a modification to Larsen's score [12]. To
check whether scoring was consistent, 10% of films were
selected at random and returned for repeat blinded analysis. A
weighted kappa score was calculated to quantify the intra-
observer variation in the modified Larsen scoring. The
weighted kappa score was 0.83, indicating very good agree-
ment between the initial and repeat scores.
Antibody measurement and genotyping
Anti-CCP levels were measured using the DIASTAT™ anti-
CCP ELISA (Axis-Shield, Cambs, UK). The semiquantitative
protocol was used as recommended by the manufacturer and
a cut-off of 5.5 units/ml was established based on mean plus
three standard deviations of values obtained from 100 age-
matched control individuals. RF was measured using a neph-
elometric method on the Dade Behring BN2 nephelometer.
Genotyping for DRB1 alleles was performed using polymer-
ase chain reaction based methods [13]. The following DRB1
alleles were classified as SE alleles: *0101, *0102, *0104,
*0401, *0404, *0405, *0408, *0409, *0410, *0413, *0416,
*0419, *0421 and *1001.
Statistical analyses
Quantitative variables were compared between groups by
Student's t-test or by one-way analysis of variance, as appro-
priate. Proportions of anti-CCP-positive individuals were com-
pared between subgroups by χ2 tests with two degrees of
freedom and are described as odds ratios with 95% confi-
dence limits derived using Miettinen's test-based approxima-
tion.
Results
Characteristics of the study population
A total of 872 individuals were included in the cohort. The
mean disease duration was 18 years (range 3–65 years).
Mean age at onset was 41 years (range 17–80 years) and
mean age at assessment was 59 years. The proportion of
females in the cohort was 73%. The majority of patients
Table 1
Radiographic damage in patients stratified for RF and anti-CCP status
Antibody status n Larsen's score (mean ± SEM) P
RF positive 552 49.1 ± 1.7 <0.0001a
RF negative 268 33.0 ± 1.9
Anti-CCP positive 672 46.9 ± 1.5 <0.0001a
Anti-CCP negative 159 31.3 ± 2.4
RF positive/CCP positive 493 49.6 ± 1.8 <0.0001b
RF positive/CCP negative 39 37.6 ± 5.2
RF negative/CCP positive 143 37.2 ± 2.7
RF negative/CCP negative 109 28.0 ± 2.8
Shown is an analysis of radiographic damage, as assessed by modified Larsen's score, in patients stratified for RF and anti-CCP status. at-test. 
bComparison of four groups by analysis of variance. anti-CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; SEM, standard 
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(93.7%) had been treated with disease-modifying agents. Nei-
ther disease duration nor the proportion of DMARD (disease-
modifying antirheumatic drug)-naïve individuals was signifi-
cantly different between the subgroups analyzed in Tables 1,
2, 3 below (data not shown).
Association among radiographic outcome, RF and anti-
CCP status
In our cohort both anti-CCP and RF were strongly associated
with radiographic severity, as measured using Larsen's score
(P < 0.0001), as was reported previously (Table 1). Addition-
ally, in subgroups stratified for both anti-CCP and RF status
we found evidence of independent associations of both RF
and anti-CCP with radiographic outcome. Those with both RF
and anti-CCP expressed the most severe disease (mean
Larsen's score 49.6); those with RF but not anti-CCP, or with-
out RF but with anti-CCP were intermediate in terms of sever-
ity; and double-negative patients had the mildest disease (P <
0.0001, analysis of variance).
Association between SE copy number and radiographic 
outcome in patients stratified for RF and anti-CCP
We next examined the potential influence of SE alleles on radi-
ographic outcome in our cohort by determining associations
between copy number of SE alleles and Larsen's score in
patients stratified for both RF and anti-CCP status. A weak
association of SE alleles with radiographic severity was found
only in RF-negative patients, with evidence of a gene-dose
effect (Table 2). Although a trend toward an association
between SE copy number and radiographic outcome was
seen in the cohort as a whole (Table 2), this was not statisti-
cally significant. Notably such a trend was not apparent in anti-
CCP-positive or anti-CCP-negative subgroups.
SE copy number is associated with anti-CCP status
Because both anti-CCP positivity and levels have been asso-
ciated with SE status, we were interested in the magnitude of
this association in our cohort. We also found strong associa-
tions between carriage of SE alleles and anti-CCP status, with
evidence of a gene-dose effect (Table 3). This was statistically
significant both in the cohort as a whole as well as in RF-pos-
itive and RF-negative subgroups, but the magnitude of this
Table 2
Radiographic damage among patients with two, one, or no copies of SE alleles stratified according to RF and anti-CCP status
Antibody status Number of SE alleles n Larsen's score (mean ± SEM) P (SE2 versus SE1 versus SE0)
All 2 266 46.5 ± 2.3 NS
1 393 43.6 ± 1.9
0 168 39.2 ± 2.6
RF positive 2 177 49.5 ± 2.9 NS
1 253 49.4 ± 2.5
0 94 47.0 ± 3.7
RF negative 2 71 39.0 ± 4.3 0.0458a
1 120 32.3 ± 2.7
0 65 25.9 ± 3.1
CCP positive 2 226 49.1 ± 2.5 NS
1 312 45.7 ± 2.1
0 98 44.3 ± 3.4
CCP negative 2 30 32.0 ± 5.9 NS
1 67 32.3 ± 3.7
0 58 29.2 ± 3.9
Shown is an analysis of radiographic damage among patients with 2 (SE2), 1 (SE1) or no (SE0) copies of SE alleles stratified according to RF and 
anti-CCP (shortened to CCP) status. aBy analysis of variance. anti-CCP, anti-cyclic citrullinated peptide antibody; NS, not significant; RF, 
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effect was maximal in RF-negative patients, with an odds ratio
of 6.16 for anti-CCP positivity in individuals with two SE alleles
compared with none. Conversely, the magnitude of this effect
was smallest in the RF-positive patients. We found no associ-
ation between SE copy number and RF status in a similar anal-
ysis (data not shown).
Discussion
Clarification of the relationship between DRB1 alleles, RF,
anti-CCP and disease severity remains a matter of considera-
ble importance both clinically (prediction of disease pheno-
type and the design of clinical trials/studies) and because of
the pathogenetic insights that may result. Recent studies have
highlighted the association between anti-CCP and radio-
graphic progression in early RA. However, because RF and
anti-CCP coexist in the majority of individuals with RA, few
studies examining the influence of anti-CCP on disease sever-
ity have been sufficiently powered to stratify for RF status. In
one such study of radiographic progression [14], the pres-
ence of RF independently of anti-CCP did not appear to influ-
ence progression of early disease. We found that anti-CCP
antibodies are strongly associated with radiographic outcome
in a cross-sectional cohort with established disease. In our
study the presence of RF alone and anti-CCP alone were
associated with similar radiographic outcomes, with patients
without either antibody clearly accumulating less damage. This
finding suggests that both RF and anti-CCP are independent
severity factors for RA.
The association between SE alleles and radiographic outcome
in RA has been extensively debated [15]. The situation is con-
sidered to be complex, with ethnic background and other fac-
tors playing significant roles. Most recent analyses [8]
suggested that the primary association of SE alleles is with the
development of erosions, especially in RF-negative individuals
[9,10]. The influence of SE alleles on severity of radiographic
damage is less clear, but again there is evidence of an associ-
ation in RF-negative individuals [7]. We also found a weak
association between SE copy number and severity of radio-
graphic damage in RF-negative patients only. In our cohort
anti-CCP status was strongly associated with the SE, as has
been reported previously, but a clear gene-dose effect was
also evident. The magnitude of this effect was most striking in
RF-negative patients, which supports the view that the associ-
ation of SE with radiographic severity may be indirect and due
to an association with anti-CCP. Because the proportion of
RF-positive/SE negative individuals who were anti-CCP posi-
tive was still very high, at 83%, this may explain why no asso-
ciation between SE and radiographic severity was seen in this
group.
The large sample size of our study is a strength and allows
robust subgroup analyses; however, the cross-sectional
design and selection of patients with longstanding and more
severe (erosive) disease do raise the possibility of selection
bias, and therefore the findings may not be generalizable to
populations with milder disease. Nevertheless, we believe that
our findings have some direct practical implications. They sug-
gest that determinations of RF and anti-CCP have at least
equivalent value in predicting the severity of radiographic dam-
age in RA, with typing of DRB1 alleles being likely to provide
little added information. They also support the concept that
Table 3
Association between SE alleles and anti-CCP status
RF status Number of SE alleles Proportion anti-CCP positive OR (95% CI) P
All 2 214/241 4.94 (2.94–8.22) <0.001
1 307/373 2.90 (1.89–4.43)
0 98/159 1
RF positive 2 162/170 4.15 (1.79–9.58) <0.01
1 236/253 2.85 (1.41–5.77)
0 78/94 1
RF negative 2 52/71 6.16 (3.00–12.6) <0.001
1 71/120 3.26 (1.74–6.11)
0 20/65 1
Absolute numbers of anti-CCP-positive patients in each subgroup are given. OR with 95% CI are shown for anti-CCP positivity associated with 
carriage of two or one SE allele versus no SE alleles for RF positive, RF negative and combined subgroups. P values are for χ2 tests with two 
degrees of freedom comparing the proportion of anti-CCP positive patients in subgroups carrying two, one, or no SE alleles. anti-CCP, anti-cyclic 
citrullinated peptide antibody; CI, confidence interval; NS, not significant; OR, odds ratio; RF, rheumatoid factor; SEM, standard error of the mean.Available online http://arthritis-research.com/content/8/4/R128
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anti-CCP positive disease is a distinct pathogenetic entity
associated with SE alleles, and that different pathways are
responsible for driving the production of anti-CCP and RF.
Conclusion
We demonstrated that radiographic severity of RA is associ-
ated independently with both RF and anti-CCP. In addition, the
finding that SE alleles are more strongly associated with anti-
CCP in RF-negative individuals provides an explanation for the
previously reported observation that SE alleles are only asso-
ciated with radiographic severity in RF-negative individuals.
These findings support the hypothesis that the association of
SE alleles with RA severity may be secondary to anti-CCP
positivity.
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